Requip

Parkinson Disease, Parkinson's Disease, Primary + 2 more
Treatment
7 FDA approvals
20 Active Studies for Requip

What is Requip

RopiniroleThe Generic name of this drug
Treatment SummaryRopinirole is a medication used to treat Parkinson's disease and restless legs syndrome. It was first approved by the FDA in 1997 for the management of Parkinson's disease and in 2005 for the treatment of restless legs syndrome. In 2008, extended-release capsules of ropinirole were approved, allowing for less frequent dosing, improved compliance, and similar side effects and effectiveness as older formulations of ropinirole. This medication is manufactured by GlaxoSmithKline Pharmaceuticals and is sold under the brand name ReQuip.
Requipis the brand name
image of different drug pills on a surface
Requip Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Requip
Ropinirole
1997
379

Approved as Treatment by the FDA

Ropinirole, otherwise called Requip, is approved by the FDA for 7 uses such as Severe restless legs syndrome (RLS) and Parkinson's Disease (PD) .
Severe restless legs syndrome (RLS)
Parkinson's Disease (PD)
Helps manage Parkinson's Disease (PD)
Moderate restless legs syndrome (RLS)
Primary
Restless Legs Syndrome
Restless Legs Syndrome
Parkinson's Disease
Helps manage Parkinson's Disease (PD)

Effectiveness

How Requip Affects PatientsRopinirole is used to treat Parkinson's and restless leg syndrome. It helps by stimulating the dopamine receptors, which control movement. Taking this drug may cause low blood pressure and make it drop further when standing or sitting up quickly. It may also cause nausea, bradycardia, and syncope. Ropinirole can lower the amount of prolactin in the body at doses as small as 0.2 mg. It has no effect on the heart rate or QT interval at doses up to 4 mg per day, but it is not known if it affects these things at higher doses.
How Requip works in the bodyRopinirole is an effective medicine for Parkinson's disease and Restless Legs Syndrome. It works by targeting dopamine receptors in certain areas of the brain, primarily the D3 receptors. These receptors help control body movement, and by stimulating them, ropinirole helps reduce symptoms. This drug does not affect other receptors, such as alpha2 adrenoreceptors or serotonin-1 receptors, so it does not produce any unwanted side effects.

When to interrupt dosage

The recommended measure of Requip is based upon the diagnosed condition, including Restless Legs Syndrome, Restless Legs Syndrome and Parkinson's Disease. The dosage likewise depends upon the manner of delivery as listed in the table beneath.
Condition
Dosage
Administration
Restless Legs Syndrome
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Restless Legs Syndrome
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Parkinson Disease
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Parkinson's Disease
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Primary
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

Requip Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Ropinirole may interact with Pulse Frequency
There are 20 known major drug interactions with Requip.
Common Requip Drug Interactions
Drug Name
Risk Level
Description
Acebutolol
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Acebutolol.
Aliskiren
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Aliskiren.
Ambrisentan
Minor
Ropinirole may increase the hypotensive activities of Ambrisentan.
Amifostine
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Amifostine.
Amiloride
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Amiloride.
Requip Toxicity & Overdose RiskOverdosing on Ropinirole may cause agitation, chest pain, confusion, drowsiness, unusual facial movements, grogginess, increased jerky motions, dizziness or lightheadedness when standing, nausea, and vomiting. In animal studies, there was an increase in testicular tumors in rats and benign uterine polyps in mice at higher doses. Ropinirole was not found to be mutagenic or clastogenic. In female rats, ropinirole disrupted implantation at high doses. Pregnant women should not take Ropinirole due to the potential for adverse effects on the developing fetus
image of a doctor in a lab doing drug, clinical research

Requip Novel Uses: Which Conditions Have a Clinical Trial Featuring Requip?

51 active clinical trials are presently being conducted to assess the potential of Requip in alleviating Restless Legs Syndrome, Parkinson Disease and other Restless Legs Syndrome-related afflictions.
Condition
Clinical Trials
Trial Phases
Parkinson Disease
8 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable
Restless Legs Syndrome
6 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 2
Primary
0 Actively Recruiting
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
Restless Legs Syndrome
0 Actively Recruiting

Requip Reviews: What are patients saying about Requip?

5Patient Review
12/31/2014
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
My restless legs were affecting me any time of the day and night. I could not sit still in business meetings, go out to dinner, go to the movies, or sleep at night. I occasionally had symptoms in my arms, also. I started with small doses of Requip, but now take 4mg time release in the morning and 1 mg before bed.
5Patient Review
3/31/2016
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
Requip has been a game-changer for me and my sleep patterns. I no longer have to dread going to bed, knowing that it'll be another restless night of pain.
5Patient Review
7/27/2016
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
I no longer suffer from debilitating leg and ankle cramps since I started this medication.
4Patient Review
6/9/2014
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
At first, I didn't mind the nausea and stomach pain because this drug seemed to be effective in alleviating my RLS symptoms. However, as time has gone on, the symptoms have gotten worse and now they're even affecting me while driving. I feel like the medicine made the problem more unbearable than it was to start with.
4Patient Review
4/29/2017
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
I've had RLS for many years now, and it's mostly a nightly occurrence. This medication help me get through the evening without too much discomfort. The only downside is that I sometimes feel sleepy and have chest tension.
4Patient Review
7/17/2014
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
This treatment does a good job, but I have experienced severe diarrhea as a side effect.
3.7Patient Review
2/3/2016
Requip for Parkinson's Disease
This drug does help with RLS, but it also makes me very sleepy. After taking it, I'm out like a light within two hours. However, my leg twitches have stopped while sleeping. It's not something I can take during the day though.
2.7Patient Review
4/13/2022
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
I had to stop taking ropinerole because it started causing me severe stomach pain, nausea, and sometimes vomiting. I tried upping the dosage, but that only made things worse. I've had a CT scan and everything looks normal, so I don't know what the issue is. But I just can't take it anymore.
1.7Patient Review
1/1/2016
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
I've been taking the medication for a while now, and it doesn't seem to be as effective. I'm constantly tired, my joints hurt, and I have a cough that just won't go away. Not sure if it's related to the meds or not, but I'm going to try something else soon.
1Patient Review
11/11/2015
Requip for Parkinson's Disease
While this drug did help me with my RLS, I developed sores on my vulva after only a week of use. Once I stopped taking the medication, they cleared up immediately. I'm not sure if it was the 2mg dosage or what, but I'll be asking my doctor to prescribe something else.
1Patient Review
10/9/2017
Requip for Extreme Discomfort in Calves when Sitting or Lying Down
I was prescribed Requip for my RLS, but it made the condition worse and almost killed me. I experienced serious side effects like muscle tremors and dehydration, which landed me in the ER. Do not take this medication!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about requip

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Requip help with anxiety?

"The text states that ropinirole not only helps with motor symptoms, but also with anxiety and depression. The changes in mood and anxiety are linked to changes in sleep patterns."

Answered by AI

Is Requip a pain pill?

"Requip is a medication used to treat symptoms of Parkinson's disease, such as stiffness, tremors, muscle spasms, and poor muscle control. It is also used to treat restless legs syndrome."

Answered by AI

What is the drug Requip used for?

"This medication is used to treat Parkinson's disease either by itself or combined with other medications. It can help improve your ability to move, reduce tremors, stiffness, slow movement, and lack of balance. It can also reduce the number of times you can't move ("on-off syndrome")."

Answered by AI

Is Requip a muscle relaxer?

"Requip is a medication used to treat symptoms of Parkinson's disease and restless legs syndrome. It is a dopamine agonist and is available in generic form."

Answered by AI

Clinical Trials for Requip

Have you considered Requip clinical trials? We made a collection of clinical trials featuring Requip, we think they might fit your search criteria.Go to Trials
Image of London Health Sciences Center.London ,Ontario in London, Canada.

Wearable Technology for Parkinson's Disease

18+
All Sexes
London, Canada
This study aims to evaluate whether wearable technology can improve the management of motor symptoms in people with Parkinson's disease (PD) who experience motor fluctuations throughout the day. The project will use a smartwatch and mobile app (KinesiaU) to continuously track movement, allowing for more responsive and personalized treatment compared to traditional monitoring methods. In this pilot randomized controlled trial, 32 participants will be assigned to either: A control group receiving standard care, or A wearable device group receiving standard care plus using the smartwatch. Outcomes will be assessed over a 4-week period, focusing on changes in motor function, quality of life, and self-management. The study will also examine feasibility, adherence, and data quality. If successful, this trial will provide critical evidence for integrating wearable devices into routine clinical care for PD, paving the way for larger efficacy trials and more patient-centered care strategies.
Waitlist Available
Has No Placebo
London Health Sciences Center.London ,Ontario (+1 Sites)
Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD
The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment
Phase 1 & 2
Waitlist Available
Kennedy Krieger InstituteAlison E Pritchard, PhD
Image of University of Florida, Norman Fixel Institute for Neurological Diseases in Gainesville, United States.

Deep Brain Stimulation for Parkinson's Disease

45 - 85
All Sexes
Gainesville, FL
Nearly one-million people in North America are now living with Parkinson's disease (PD), and that number is projected to rise to nearly 1.2 million by 2030. With advancements in neuromodulatory technologies, increasingly more of these individuals elect to undergo deep brain stimulation (DBS) surgery in order to control symptoms of the disease, including refractory tremor, medication-induced dyskinesias, and PD-associated dystonia. The two most common DBS neural targets for controlling these symptoms are the globus pallidus internal segment (GPi) and the subthalamic nucleus (STN). Recent meta-analyses have shown relative equivalence between these two sites at controlling core PD symptoms. To date, there is not conclusive evidence regarding the potential impact of DBS to GPi or STN on laryngeal-mediated functions of voice, swallowing, and cough, and consequently no guidance on whether these outcomes should be considered when selecting DBS target. Therefore, the goal of this project is to determine the impact of DBS neural target (STN versus GPi), lead location within the target, laterality, and stimulation settings on voice, swallow and cough function in people with PD. The larynx is an important player in each of these functions, and our central hypothesis is that spread of stimulation to corticobulbar fibers in the genu of the internal capsule have deleterious effects on laryngeal motor control, resulting in voice, swallow, and cough dysfunction. We have identified three specific aims for this application: 1.) To compare laryngeal function during volitional voice tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 2.) To compare laryngeal function during volitional and induced cough tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 3.) To compare airway safety associated with laryngeal onset, degree, and duration of maximum closure during swallowing, pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. These hypotheses were developed based on compelling published and unpublished preliminary data. We will accomplish these aims by enrolling people with PD who are being considered for DBS surgery. We will measure physiologic, functional, and quality of life parameters of voice, swallow and cough pre- and post-surgically. The realization of the proposed aims is significant because it will address a substantial gap in our understanding of DBS outcomes related to communication and airway protection, which are important in terms of morbidity, mortality, and quality of life for patients with PD. The translational potential to provide additional guidance to DBS surgical teams regarding whether voice, swallow or cough functions should be considered with selecting DBS target and/or laterality is high. Ultimately, the project fits squarely within the overarching goal of the research team to deliver the best possible care to people with PD.
Recruiting
Has No Placebo
University of Florida, Norman Fixel Institute for Neurological DiseasesKaren Hegland, Ph.D.
Have you considered Requip clinical trials? We made a collection of clinical trials featuring Requip, we think they might fit your search criteria.Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Cannabis for Restless Legs Syndrome

18+
All Sexes
Toronto, Canada
Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.
Recruiting
Drug
Sunnybrook Health Sciences Centre (+1 Sites)
Image of Integrated Health and Movement Science Laboratory, Saint Louis University in St. Louis, United States.

Community Walking Program for Parkinson's Disease

30 - 85
All Sexes
St. Louis, MO
This study will investigate the feasibility of a 6-month community walking program for people with Parkinson's disease (PD) and their care partners in greater Saint Louis, Missouri region. The walking program will consist of weekly, organized walking groups at the Missouri Botanical Gardens. Participants in the program will use Nordic walking poles during the walks. The walking group(s) will meet once per week and will be supervised by walking group leaders from Saint Louis University. Participants will be given a smart watch to wear that will help step counts will be tracked in real-time. The program is designed to get people with Parkinson's disease out of their homes, cultivate a culture of connection with others with Parkinson's disease, and to be collectively accountable for a common goal toward increasing their physical and social engagement in their communities.
Recruiting
Has No Placebo
Integrated Health and Movement Science Laboratory, Saint Louis University (+1 Sites)
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Have you considered Requip clinical trials? We made a collection of clinical trials featuring Requip, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security